Biomarkers 2025

12 - 14 February 2025 | London, UK

Europe’s flagship event for biomarkers technological innovation returns: advancing biomarkers in drug discovery, development, clinical trials and accelerating precision medicine

Explore Biomarkers 2025: Challenges Across the Biomarkers Value Chain to Enable Discovery & Development

Join us for the 20th Annual Biomarkers & Precision Medicine Congress, an immersive experience designed to unveil the forefront of biomarker trends and tools. This event assembles top experts from global pharmaceutical organizations, groundbreaking biotech companies, and esteemed academic institutions, all engaged in diverse therapeutic areas and stages of drug development, clinical trials and precise patient treatments.

20th Annual Biomarkers & Precision Medicine Congress

  • 3-day programme to hear from and share insights with key innovators from pharma and healthcare in biomarkers discovery, development, translational research, clinical trials & clinical development, precision medicine and diagnostic strategies 
  • Gain invaluable insights into the latest advancements in the integration of biomarkers in early drug development through unique case studies across multiple therapeutic areas. Key opinion leaders will be presenting on NASH, cardiovascular disease detection, rare & autoimmune diseases and oncology, immune-oncology & neuroscience 
  • Discover collaborative solutions for digital transformation, digital biomarkers and data-driven approaches. Presentations will cover digital biomarkers for disease detection and monitoring; integration of digital health technologies & devices, AI/ML approaches and RWE & biomarker data analysis 
  • Discuss the latest innovations in navigating regulatory barriers in clinical trials & CdX and complex biomarkers. From in vitro diagnostics regulations and quality environment for quality testing through to how regulators can support the development and adoption 
  • Tap into enabling precision medicine in diagnostics & development. Key opinion leaders will be covering developing nextgen diagnostics methods as well as case studies from oncology, autoimmune diseases and neuroscience  
  • A high-quality programme devised with the help of our esteemed advisory board & steering committee. Presentations will cover integrating multi-omics data, capturing complex clinical phenotype and cell & gene biomarkers as innovative approaches to treat rare diseases 

Agenda at a Glance


Day One: 

  • Track 1: Biomarkers for NASH, Cardiovascular Diseases Detection 
  • Track 2: Biomarkers for Rare & Autoimmune Disease 
  • Track 3: Digital Transformation & Digital Biomarkers & Data Science & AI/ML 
  • Track 4: Navigating Regulatory Barriers in Clinical Trials & CdX and Complex Biomarkers 

Day Two:

  • Track 1: Biomarkers Identification, Validation in Oncology, Immuno-Oncology & Immunology
  • Track 2: Enabling Precision Medicine for Diagnostics & Development 
  • Track 3: Biomarkers for Clinical Development 
  • Track 4: Spatial Tissue Imaging & Imaging and AI for Biomarker Research

Day Three:

  • Track 1: Biomarkers Identification & Validation: Neuroscience & Co-Morbidity 
  • Track 2: New & Emerging Biomarker Technologies for Biomarker Analysis 
  • Track 3: Biomarkers for Clinical Trials 
  • Track 4: Genomic & Multi-Omic Approaches in Biomarkers Discovery and Development 

 

25f1494b-ec1b-4180-820e-7721ad50e98f-2-5668375logo-UBS-logo-AW-RGB

The Oxford Global team were fantastic to work with and helped make the organisation and scheduling of my conference seamless. I was not able to attend in person however the team ensured that all my meetings were arranged online so I could still participate. The team ensured that these meetings ran smoothly and efficiently. The leads that I have generated from the conference are very exciting and I am sure I will be attending again in the future.


Alex Certoma
Corporate Analyst, Universal Biosensors

Sanofi

Very productive meeting with precisely the right vendors for biomarker research.

Global Head of Biomarkers
Sanofi

Canopy Biosciences

Always enjoyed exhibiting at Oxford Global conferences as they are well organised from initial interest to the day of the event itself. The committee ensure all scheduled 1-2-1 meetings are attended and will also re-schedule if necessary. Venues have been spacious, and the catering has been of excellent quality including the desserts!


Paru Oatey
Business Development Manager – Northern Europe, Canopy Biosciences® – A Bruker Company

Abzu

I liked the high scientific level of the event and the great organisation, which left enough time for networking and the exchange of ideas and thoughts outside the regular agenda.


Marco Salvatore

Head of Target & Biomarker Discovery, Abzu

Sanofi

Very well organised event. The format was very suitable and sending meeting requests through the app worked very effectively.


Precision Medicine Head

Sanofi

Sapient Bioanalytics

Biomarkers UK is one the best organized conferences that we have attended. Oxford Global was very focused on helping us make the most of the event, from coordinating multiple high-value meetings on our behalf to giving us tools like the Swapcard app to make networking simple and effective. They provided an engaging program and gave us a platform to meet with like-minded individuals who believe in the transformative impact of biomarkers and had real interest in our offerings.


Tanya Nguyen

Head of Scientific Operations, Sapient

ONO Pharma

The conference was well organised, covering a wide range of important scientific topics relating to biomarkers.


Clinical Science Director

Ono Pharma UK Ltd

What to Expect

1000

leading pharma, biotech, healthcare & academic delegates

30
hours of presentations, discussions & interactive content
12
hours of networking breaks, including speed networking & refreshments
200
hours of pre-arranged 1-2-1 meetings, facilitating business growth
What to Expect Engaging Thought Leadership-1
What to Expect Global Technological Showcase-1
What to Expect Networking Emphasis-1
What to Expect Innovative Poster Displays-1

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Experience over 30 dynamic interactive discussions, C-level debates, collaborative roundtables, and thought-provoking presentations & innovation showcases curated with insights from top industry leaders and experts to benchmark your research & development pipeline
  • Global Technological Showcase

    An international & dynamic exhibition showcasing cutting-edge technologies and services from premier providers in the scientific field
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, personalised 1-2-1 meetings, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays & Awards Ceremony

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and start up companies

Key Themes for Biomarkers 2025

The 2025 programme will delve into the intricacies of navigating regulatory barriers in clinical trials, with a specific focus on companion diagnostics (CdX) and the complexities of biomarkers. Discussions will also revolve around the pivotal role of biomarkers in clinical development, exploring advancements in spatial tissue imaging and the integration of AI technologies in biomarker research. With precision medicine also at the forefront, key opinion leaders will examine how these innovations are shaping the landscape of healthcare and the future of personalized treatment approaches within clinical trials. 

Companies Represented Include

Biotech Innovation & Collaboration

Inspiring Tomorrow's Breakthroughs: Unleashing Innovation & Collaboration in Biomarkers Research & Development

Join engaging presentations featured in our innovation and collaboration track running across day 2 and 3, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.  

The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biomarkers discovery & development.

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:  

  • Seeking collaboration partners with pharma and solution providers 
  • Discovering new investment opportunities with pharma 
  • Learning about the latest industry trends & challenges  
  • Keeping updated with new innovations and technology solutions 
  • Showcasing their company profile to a targeted and engaged audience

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The Biomarkers Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist. 

Please submit your poster presentation by no later than 20th December 2024 in the below category: 

  • Emerging Technologies  
  • Biomarkers in Therapeutics  
  • Biomarkers in Diagnostics  
  • Biomarkers in Clinical Trials & Precision Medicine  
  • Omics-Based Biomarker Discovery
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 20th December 2024
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 20th December 2024 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the Biomarkers series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

For further information contact help@oxfordglobal.com

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Biomarkers 2024: 29 February - 01 March 2024, London, UK

Alexandra Sevko
Director, Translational Research,
Prokarium
Anders Ståhlberg
Professor,
University of Gothenburg
Andrew Pierce
Vice President, Translational Biology,
Crescendo Biologics
David Krige
Head of translational sciences,
David.krige@accessiontherapeutics.com
Gerard Sanderink
Global Head Biomarkers & Clinical Bioanalysis,
Sanofi
Henoch Hong
Associate Director,
Merck Healthcare KGaA
Kimberly Kraynyak
Principal Scientist, Translational Oncology,
Merck Life Science KGaA
Kira Holmstrom
Head of Biomarker Research,
Herantis Pharma
Kiri Granger
Chief Scientific Officer,
Monument Therapeutics
Kon Yew Kwek
Senior Vice President and Clinical Development,
Hummingbird Bioscience
Mohamed Hassanein
Director, Translational Medicine,
Pfizer
Paul Skipp
Professor of Proteomics,
University of Southampton

All Speakers

Amanda Heslegrave
Senior Research Fellow,
University College London
Anna Ettorre
Director of Translational Science,
AviadoBio Ltd
Anne Remaury
Principal Scientist in Bioanalysis,
Sanofi
Bangwen Xie
Clinical Biomarker Data Operations Manager,
GSK R&D
Belinda Nedjai
Associate Professor,
Queen Mary University of London
Chris Chamberlain
Head of Precision Medicine Discovery and Development,
AstraZeneca
Christopher Peters
Clinical Senior Lecturer,
Imperial College London
Debayan Mukherjee
Principal Scientist,
GSK
Desiree Schenk
Principal Scientist,
Gritstone Oncology
Dmitri Mikhailov
Director,
Novartis
Donna Finch
Head of Translational and Clinical Science,
Alchemab Therapeutics
Donna Finch
Head of Translational and Clinical Science,
Alchemab Therapeutics
Elizabeth Harrington
Executive Director, Translational Medicine,
AstraZeneca
Emilyanne Leonard
Associate Director,
AstraZeneca
Emma Leire
Director,
Achilles Therapeutics
Gabriela Kramer-Marek
Group Leader,
The Institute of Cancer Research
Gad Simchoni Cojocaru
scientist,
Cgen
Giovanna Lalli
Director, Strategy & Operations,
LifeArc
Graham Ball
Director of the Medical Technology Research Centre,
Anglia Ruskin University
Hans-Dieter Volk
prof,
charité
Irene del Molino del Barrio
Principal Scientist,
GSK
Jeremy Magnanensi
Project Manager - Biostatistician Biomarkers R&D,
Genfit
Jose MG Izarzugaza
Head of Department,
Novo Nordisk
Kathrin Heinzmann
Biomarker Scientist,
Cancer Research UK
Kristian Moss Bendtsen
Data Scientist,
Novo Nordisk
Leonor Benhaim
Doctor,
INSERM
Malgorzata Oczko-Wojciechowska
Professor,
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch
Maria Udriste
Senior Scientist,
AstraZeneca
Patrick Fivey
Director of Precision Medicine Policy,
AstraZeneca
Rita Vicente
Senior Principal Scientist, Head of the Immunology Laboratory,
Sanofi
Rupesh Kanchi Ravi
Senior Director, ADO BioPharma,
Fulgent Pharma
Stephanie Craig
Lecturer in Precision Medicine,
Queen's University Belfast
Steven Piccoli
Head of Clinical Biomarkers,
SPARC
Steven Piccoli
Head of Clinical Biomarkers,
SPARC
Thomas Jensen
CEO,
Allarity Therapeutics
Thomas Hach
Executive Director Patient Engagement, Cardiovascular, Renal & Metabolism Patient Engagement,,
Novartis
Tim Aitman
Professor of Molecular Pathology and Genetics,
University of Edinburgh

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

Early Diagnostic Blood Biomarker for Dementia Identified Using Proteomics

The team hopes to develop the biomarker into a test that could be used in GP surgeries. Early prediction of dementia could be a gamechanger for new Alzheimer's therapies.

Investigating Biases in Diagnostics and Biomarkers: Three Case Studies

In the quest to improve diagnostics, new technologies are key, but so is overcoming entrenched bias.

Machine Learning Metabolomics Approach Used to Diagnose Ovarian Cancer

Researchers have used an artificial intelligence model to analyse the metabolites of patients with or without ovarian cancer and have reported shocking accuracy of diagnosis.

Enhancing Patient Care: Exploring the Role of Digital Biomarkers in Patient-Centric Healthcare

Digital biomarkers, collected from wearables and apps, are reshaping patient-centered healthcare with real-time insights and personalized care. Challenges like data privacy and interoperability require collaboration between healthcare, tech, and regulators for full integration.

Using Biosensors for Biomarker Identification and Validation in Lung Cancer

Advancements in biosensors, notably graphene-based ones, show promise in swiftly identifying elusive lung cancer biomarkers, potentially revolutionising early diagnosis.

How Digital Biomarkers Can Enhance Pathologies and Patient Care

Digital biomarkers hold promise for healthcare, offering improved rare disease detection and cost reduction, with the potential for future implementation in clinical healthcare settings.

Plan Your Visit

Oxford Global have secured a number of bedrooms at Novotel London West at a reduced rate:

Wednesday 28th February 2024 – £190 including VAT and breakfast

Thursday 29th February 2024 – £190 including VAT and breakfast

*Please note: £10 supplement is applicable for double occupancy

Should you wish to book a room, please email help@oxfordglobal.com. The final cut-off date to book bedrooms is Monday 12th February 2024 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to cancellation charges.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biomarkers 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch